Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06833112 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

Name: Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis — clinical trial record (NCT06833112)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorThe Affiliated Hospital Of Guizhou Medical University

Started2025-02

View on ClinicalTrials.gov ↗

The Affiliated Hospital Of Guizhou Medical University

8 trials monitored

See all monitored trials

Ankylosing Spondylitis

176 trials monitored

See 6 trials at risk

The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.

Trial Details

NCT Number	NCT06833112
Lead Sponsor	The Affiliated Hospital Of Guizhou Medical University
Conditions	Ankylosing Spondylitis
Enrollment	10 participants
Start Date	2025-02
Primary Completion	2027-08 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2025-02-18